SCHEMBL221207

SCHEMBL221207

NC(=O)N(S)c1cc(Br)cc(OCc2ccccc2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PARP10 Q53GL7 2/20 0.46
ALOX5 P09917 2/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
PARP15 Q460N3 1/20 0.43
PARP14 Q460N5 1/20 0.43
PTGES O14684 1/20 0.42
NR4A2 P43354 2/20 0.42
NR4A1 P22736 1/20 0.41
NR4A3 Q92570 1/20 0.41
SMPD1 P17405 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SPHK2 Q9NRA0 1/20 0.41
SPHK1 Q9NYA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9537720 0.81 PARP10 (0.60) MAOBPARP10ALOX5NR4A2NR4A1
SCHEMBL27995327 0.77 PARP10 (0.63) MAOBMEN1KMT2APARP10MRGPRX4
SCHEMBL10046165 0.75 MAOB (0.72) MAOBMEN1KMT2AALOX5MRGPRX4
SCHEMBL308991 0.75 MAOB (0.72) MAOBMEN1KMT2AALOX5MRGPRX4
SCHEMBL14251338 0.74 MEN1 (0.79) MAOBMEN1KMT2AMRGPRX4NR4A2
SCHEMBL219166 0.73 PARP1 (0.32) ALOX5
SCHEMBL20472063 0.73 KMT2A (0.59) MAOBMEN1KMT2APARP10MRGPRX4
SCHEMBL31418062 0.73 MAOB (0.64) MAOBMEN1KMT2AALOX5MRGPRX4
SCHEMBL222509 0.72 NPC1 (0.45) MAOBMEN1KMT2AMRGPRX4NR4A2
SCHEMBL9371922 0.71 MAOB (0.67) MAOBMEN1KMT2AMRGPRX4NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481544-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-07-09 US disclosed
US-8389516-B2 Antibacterial compositions BIOTA EUROPE LIMITED (GB) 2013-03-05 US disclosed
EP-2034997-B1 ANTIBACTERIAL COMPOSITIONS BIOTA EUROPE LTD (GB) 2012-10-17 EP disclosed
US-20120004221-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2012-01-05 US disclosed
US-20110263590-A1 Antibacterial Compositions BIOTA EUROPE LIMITED (GB) 2011-10-27 US disclosed
US-7977340-B2 Antibacterial compositions PROLYSIS LTD. (GB) 2011-07-12 US disclosed
US-20090197877-A1 Antibacterial Compositions PROLYSIS LTD. (GB) 2009-08-06 US disclosed
CN-101472585-A Antibacterial compositions PROLYSIS LTD (GB) 2009-07-01 CN disclosed
EP-2034997-A1 ANTIBACTERIAL COMPOSITIONS Prolysis Limited (GB) 2009-03-18 EP disclosed
WO-2007148093-A1 ANTIBACTERIAL COMPOSITIONS PROLYSIS LTD. (GB) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004221-A1 Antibacterial Compositions CYCS, COX6C, RPS6 MAOB 1148/4885MEN1 2540/4885KMT2A 3959/4885
US-20090197877-A1 Antibacterial Compositions CYCS, COX6C, INTS6 MAOB 1038/4885MEN1 3041/4885KMT2A 4428/4885
US-20110263590-A1 Antibacterial Compositions CYCS, COX6C, RPS6 MAOB 1191/4885MEN1 2542/4885KMT2A 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.